A5029972934- Medical Imaging Techniques and Applications
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Multiple Myeloma Research and Treatments
- Prostate Cancer Treatment and Research
- Advanced X-ray and CT Imaging
- Prostate Cancer Diagnosis and Treatment
- Radiation Dose and Imaging
- Protein Degradation and Inhibitors
- Radiation Therapy and Dosimetry
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Radiation Detection and Scintillator Technologies
- Lymphoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- HER2/EGFR in Cancer Research
- MRI in cancer diagnosis
- Advanced MRI Techniques and Applications
- Cancer, Hypoxia, and Metabolism
- Peripheral Neuropathies and Disorders
- Breast Cancer Treatment Studies
- Quantum Chromodynamics and Particle Interactions
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
Inserm
2013-2024
Nantes Université
2006-2024
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2014-2024
Centre National de la Recherche Scientifique
2013-2024
Institut Génétique Nantes Atlantique
2012-2024
Institut de Cancérologie de l'Ouest
2013-2024
Centre Hospitalier René-Dubos
2002-2023
Université d'Angers
2020-2022
Onco Lille
2020
Bordeaux Population Health
2018
Monte Carlo simulation is an essential tool in emission tomography that can assist the design of new medical imaging devices, optimization acquisition protocols and development or assessment image reconstruction algorithms correction techniques. GATE, Geant4 Application for Tomographic Emission, encapsulates libraries to achieve a modular, versatile, scripted toolkit adapted field nuclear medicine. In particular, GATE allows description time-dependent phenomena such as source detector...
This study aimed to assess prospectively the efficacy of sequential [18F]fluorodeoxyglucose positron emission tomography (FDG PET) evaluate early response neoadjuvant chemotherapy in stage II and III breast cancer patients.Images were acquired with a PET/computed scanner 64 patients after administration FDG (5 MBq/kg) at baseline first, second, third, sixth course chemotherapy. Ultrasound mammography used tumor size. Decrease standardized uptake value (SUV) PET was compared pathologic...
Despite the early theoretical prediction of 0+-0+ transition 90Zr, 90Y-PET underwent only recently a growing interest for development imaging radioembolization liver tumors. The aim this work was to determine minimum detectable activity (MDA) 90Y by PET and impact time-of-flight (TOF) reconstruction on detectability quantitative accuracy according lesion size.The study conducted using Siemens Biograph® mCT with 22 cm large axial field view. An IEC torso-shaped phantom containing five...
Radioimmunotherapy (RIT) has emerged as a potential treatment option for multiple myeloma (MM). In humans, dosimetry study recently showed the relevance of RIT using an antibody targeting CD138 antigen. The therapeutic efficacy anti-CD138 coupled to (213)Bi, α-emitter, was also demonstrated in preclinical MM model. Since then, with β-emitters shown treating hematologic cancer. this paper, we investigate 5T33 murine model new monoclonal labeled either (213)Bi α-RIT or (177)Lu β-RIT.A...
High hematological toxicity has been observed with anti-carcinoembryonic antigen radioimmunotherapy (RIT) in medullary thyroid carcinoma (MTC), suggesting metastatic bone involvement (BI). This retrospective study evaluated the rate of BI MTC patients enrolled two phase-I/II RIT trials using × anti-diethylenetriamine pentaacetic acid bispecific antibodies and [131I]di-diethylenetriamine hapten. Thirty-five underwent scintigraphy, magnetic resonance imaging (MRI), post-RIT immunoscintigraphy...
Syndecan-1 (CD138), a heparan sulfate proteoglycan, is constantly expressed on tumor cells in multiple myeloma (MM). This surface antigen an attractive candidate for targeted therapy, especially radioimmunotherapy (RAIT). We report preliminary biodistribution and dosimetry results obtained refractory MM patients phase I/II RAIT study using iodine-131-labeled anti-CD138 (B-B4) monoclonal antibody (mAb). Four with progressive disease were enrolled after three lines of therapy. They received...
Painful peripheral neuropathy is a frequent toxicity associated with bortezomib therapy. This study aimed to identify loci that affect susceptibility this toxicity.A genome-wide association (GWAS) of 370,605 SNPs was performed risk variants for developing severe bortezomib-induced (BiPN) in 469 patients multiple myeloma who received bortezomib-dexamethasone therapy prior autologous stem cell randomized clinical trials the Intergroupe Francophone du Myelome (IFM) and findings were replicated...
Introduction: Dosimetric studies for targeted radiotherapy require the quantification of activity from scintigraphic images. Quantitative imaging is difficult to achieve because several effects that can lead errors in estimates, some which are more apparent when I-131 considered as a source. An evaluation these phenomena was performed by modeling gamma camera and its behavior using Monte Carlo simulations. Two cameras were modeled: DST-XLi Millennium VG Hawk-Eye (GEMS), two codes used: MCNP...
Dosimetric calculations are performed with an increasing frequency before or after treatment in targeted radionuclide therapy, as well for radiation protection purposes diagnostic nuclear medicine. According to the MIRD committee formalism, mean absorbed dose a target is given by product of cumulated activity and dose-conversion factor, known S factor. Standard factors have been published mathematic phantoms unit-density spheres. The accuracy results from use these questionable, because...
Abstract BACKGROUND: Maximum injected activity in radioimmunotherapy (RIT) is limited by bone marrow toxicity. Many dosimetric approaches have been proposed, leading to high variability the results and elusive absorbed dose‐effect relations. This study presents of red (RM) dose estimates performed with 3 methods. METHODS: Five patients received 2 co‐infusions 90 Y‐labeled (370 MBq/m2) 111 In‐ labeled (120 MBq) epratuzumab (1.5 mg/kg) 1 week apart. RM‐absorbed was estimated methodologies. The...
A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung cancer expressing carcinoembryonic antigen (CEA) to optimize bispecific antibody and labeled peptide doses, as well the delay between their injections.Three cohorts of three received anti-CEA × anti-histamine-succinyl-glycine (HSG)-humanized trivalent (TF2) IMP288 bivalent HSG peptide. Patients underwent a pretherapeutic imaging session S1 (44 or 88 nmol/m(2) TF2 followed by...
This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)–negative, carcinoembryonic antigen (CEA)–positive metastatic breast cancer, compared CT, bone MRI, and <sup>18</sup>F-FDG PET. <b>Methods:</b> Twenty-three underwent whole-body immuno-PET after injection 150 MBq <sup>68</sup>Ga-IMP288, histamine-succinyl-glycine peptide given initial targeting trivalent anti-CEA,...
Point kernels describe the energy deposited at a certain distance from an isotropic point source and are useful for nuclear medicine dosimetry. They can be used absorbed-dose calculations sources of various shapes also tool when comparing different Monte Carlo (MC) codes. The aim this study was to compare calculated by using mixed MC code, PENELOPE (v. 2006), with condensed-history codes, ETRAN, GEANT4 8.2), MCNPX 2.5.0). electrons initial energies 10, 100, 500, 1 MeV were simulated...
This manuscript reviews current advances in the use of radioimmunotherapy (RIT) for treatment B-cell non-Hodgkin's lymphoma (NHL). RIT has been more than 20 years and progressed significantly with discovery new molecular targets, development stable chelates, humanization monoclonal antibodies (MAbs), pretargeting techniques. Today, two products targeting CD20 antigen are approved: (131)I-tositumomab (Bexxar(®)), (90)Y-ibritumomab tiuxetan (Zevalin(®)). is available United States,...